The results of our study revealed that PD-1/PD-L1 inhibitors plus GC treatment had an ORR and DCR of 23.1% and 46.2%, respectively, in advanced ICC patients, with 6-month and 9-month OS rates of 87.4% and 71.5%, respectively. Here, PDCD1 is linked to intrahepatic cholangiocarcinoma.